Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
3 clinical-grade skincare creams you really shouldn’t buy online 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Apple Extends Qualcomm Patent Licensing Deal 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Canadian Dollar Faces Pressure as Fed-BoC Policy Gap Widens 
Dollar Holds Near Two-Month High as Yen Approaches 160 
Add as a preferred source on Google
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
